Advanced Solid Tumors
Exscientia AI Limited is involved in clinical research for advanced solid tumors, with interest in oncology settings where treatment options are limited and disease control remains challenging.
- Anti-tumor activity
- Safety
- Pharmacokinetics
- Biologic dose selection
The sponsor’s research in this area reflects a focus on therapies intended for patients with advanced malignancies across multiple tumor types.
Relapsed or Refractory B-cell Malignancies
The sponsor also supports studies in relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, Richter’s transformation, mantle-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
- Chronic lymphocytic leukemia
- Richter’s transformation
- Mantle-cell lymphoma
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Marginal zone lymphoma
This research area centers on hematologic cancers with persistent or recurrent disease after prior treatment.
Combination Oncology Regimens
Clinical activity includes evaluation of investigational therapies alongside selected standard-of-care regimens, with attention to how combination approaches may influence tolerability and tumor response in both solid and blood cancers.
- Monotherapy
- Combination therapy
- Standard-of-care regimens
- Tumor response
These studies place emphasis on aligning new treatment strategies with existing oncology practice in difficult-to-treat disease settings.
Early-Stage Clinical Oncology Development
The sponsor’s trial portfolio reflects early clinical development in oncology, with interest in defining treatment characteristics such as safety, dose selection, and preliminary efficacy signals.
- Clinical safety
- Dose determination
- Preliminary efficacy
- Anti-cancer activity
Research sites across multiple countries support the sponsor’s work in cancer indications spanning both solid and hematologic malignancies.
